Respiratory syncytial virus (RSV) causes severe lower respiratory tract infections in young 18 infants. There are no RSV-specific treatments available. Ablynx has been developing an anti-19 RSV F-specific Nanobody®, ALX-0171. To characterise the therapeutic potential of ALX-0171 20 we exploited our well-differentiated primary pediatric bronchial epithelial cell (WD-PBEC)/RSV 21 infection model, which replicates several hallmarks of RSV disease in vivo. Using 2 clinical 22 isolates (BT2a; Memphis 37), we compared the therapeutic potential of ALX-0171 with 23 palivizumab, which is currently prescribed for RSV prophylaxis in high-risk infants. ALX-0171 24 treatment (900 mM) at 24 h post-infection reduced apically released RSV titers to near or below 25 the limit of detection within 24 h for both strains. Progressively lower doses resulted in 26 concomitantly diminished RSV neutralisation. ALX-0171 was approximately 3 fold more potent 27 in this therapeutic RSV/WD-PBEC model than palivizumab (mean IC 50 = 346.9-363.6 nM and 28 1048-1090 nM for ALX-0171 and palivizumab, respectively), irrespective of the clinical isolate.
Introduction
Results 109 There was a clear dose-effect of ALX-0171 treatment on RSV BT2a and Memphis 37 growth 110 kinetics. RSV BT2a titers diminished dramatically by 24 h of treatment with 900 nM ALX-0171 111 with a 4.74 log 10 reduction in mean virus titers ( Figure 1A) . The virus was almost completely 112 neutralized by this time under these conditions and virus neutralization was maintained for the 113 duration of the experiment. Treatment with 300 nM also resulted in reductions in apically-114 released RSV BT2a, with >2 log 10 reduction in mean virus titers evident at 144 hpi relative to 115 buffer-treated RSV BT2a-infected control cultures. A less marked reduction in mean RSV BT2a 116 titers was observed following treatment with 100 nM relative to buffer-treated controls. 117 Substantial reductions were also evident in RSV Memphis 37 titers by 24 h of treatment with 900 118 nM ALX-0171, with a 4.2 log 10 reduction in mean virus titers, although low virus titers were 119 continually detectable in these cultures until 144 hpi ( Figure 1B) . Lower, but nonetheless 120 substantial, reductions in RSV Memphis 37 titers were also evident following treatment with 300 121 nM ALX-0171, whereas treatment with 100 nM did not result in substantially reduced viral 122 titers. In contrast, treatment with ALX-0171 concentrations <100 nM did not influence growth 123 kinetics of either RSV strain relative to buffer-treated control cultures under these experimental 124 conditions.
125
Unlike ALX-0171, infectious RSV BT2a was detected following treatment with all palivizumab 126 concentrations. However, there was a clear dose-effect on virus titers following palivizumab 127 treatment of RSV BT2a-infected WD-PBEC cultures. Treatment with 900 nM palivizumab 128 resulted in >2 log 10 reduction in viral titers. Treatment with 300 or 100 nM palivizumab also 129 7 resulted in substantial but lower reductions in viral titers compared to buffer-treated controls 130 ( Figure 2A ). However, treatment with 33, 11 or 4 nM palivizumab had no effect on the growth 131 kinetics of RSV BT2a.
132
Similar results were also observed in RSV Memphis 37 titers following treatment with 133 palivizumab. Treatment with either 900 or 300 nM palivizumab resulted in substantial reductions 134 in viral titers ( Figure 2B ). However, only slight reductions in mean Memphis 37 titers were 135 evident following treatment with 100 nM palivizumab. Treatment with <100 nM palivizumab 136 did not alter the growth kinetics of RSV Memphis 37 relative to the buffer control.
137
Treatment with 900 nM, 300 nM or 100 nM of either ALX-0171 or palivizumab resulted in 138 substantial reductions in RSV BT2a titers. At the highest concentration tested (900 nM), ALX-139 0171 appeared to be considerably more potent than palivizumab, reducing the viral titers to the 140 limit of detection ( Figure 3A ). The two highest concentrations of both ALX-0171 and 141 palivizumab (900 nM and 300 nM) substantially reduced the viral titers of RSV Memphis 37 142 compared to buffer-treated controls. However, treatment with ALX-0171 resulted in greater 143 reductions in viral growth kinetics compared to treatment with palivizumab at equimolar 144 concentrations, except for treatment with 100 nM of ALX-0171 or palivizumab, which showed 145 similar viral titers at each time point ( Figure 3B ).
146
The IC 50 for each treatment against each virus was calculated ( Table 1 ). The palivizumab IC 50 147 (1090 nM) was significantly higher than the IC 50 of ALX-0171 (363.6 nM) against Memphis 37.
148
Similarly, the IC 50 of palivizumab (1048 nM) against BT2a was also significantly higher than 149 that of ALX-0171 (346.9 nM). The IC 50 calculated from the area under the curves was not 150 significantly different for either ALX-0171 ((p-value = 0.751) or palivizumab (p-value = 0.858) 151 8 against the two RSV strains, indicating that both viruses had comparable sensitivities to 152 neutralisation in the WD-PBEC culture model.
153
A trend towards reduction in RSV BT2a viral loads, as determined by RT-qPCR, was evident 154 following treatment with both ALX-0171 and palivizumab. At 144 hpi, ALX-0171 900 and 300 155 nM doses reduced mean viral loads by 0.8 log 10 genome copies (GC)/mL and 1.3 log 10 GC/mL, 156 respectively, versus buffer-treated cultures ( Figure 4A ). At the same timepoint and for the same The aims of this study were two-fold: to assess the efficacy of ALX-0171 as an anti-RSV 167 therapeutic; and to evaluate the WD-PBEC model for use in pre-clinical studies. Despite 168 extensive research into RSV pathogenesis and mechanisms of disease, vaccines and treatments 169 have remained elusive. Ablynx nv has developed ALX-0171 to address the need for a RSV 170 treatment option. In this study we used our RSV/WD-PBEC model to assess the therapeutic 171 potential of ALX-0171 or palivizumab to neutralise two different clinical strains of RSV.
172
Palivizumab is the only licensed neutralising anti-RSV monoclonal antibody. It is administered 173 9 prophylactically and reserved for infants deemed at high risk of severe RSV infection, in large 174 part because of its high cost. However, the majority of children hospitalised due to severe RSV 175 infection are not classified as high-risk and, as such, do not receive palivizumab prophylaxis. A 176 therapeutic intervention that can be administered after the onset of symptoms would reduce the 177 huge economic burden of RSV and potentially reduce the number and/or duration of 178 hospitalisations.
179
Growth kinetics for both RSV Memphis 37 and BT2a followed a similar pattern in the WD-180 PBECs. Both strains reached similar peak viral titers between 72 and 96 hpi. RSV BT2a and 181 Memphis 37 demonstrated similar susceptibilities to neutralisation by ALX-0171 or 182 palivizumab. The highest concentration of ALX-0171 (900 nM) reduced viral titers to near or 183 below the limit of detection by 24 h post-treatment (~5 log 10 reduction), whereas palivizumab 184 treatment at the same concentration was less effective (~3 log 10 reduction). These differences 185 were reflected in the respective IC 50 values for both molecules.
186
The RT-qPCR data demonstrated that ALX-0171 or palivizumab treatment resulted in a trend 187 toward reduced viral replication for both RSV BT2a and Memphis 37 but this did not reach 188 significance. However, the differences were much less marked than the TCID 50 data. When the 189 TCID 50 and RT-qPCR data were considered together they suggested that both ALX-0171 and 190 palivizumab treatment resulted in efficient neutralization of RSV released from the WD-PBEC 191 cultures (TCID 50 results) but had a limited effect on intracellular virus replication. Interestingly, 192 a similar effect was seen following motavizumab administration to infants hospitalised with 193 RSV; a significant reduction in infectious viral titers was reported coincident with a much lower 194 reduction in virus copy numbers(28). However, the RT-qPCR assay does not distinguish between 195 released virus that was neutralized and virus that remained infectious, thereby masking the effect 196 of treatment. Similarly, it was shown that the natural rate of viral load decline is less steep when 197 using a RT-qPCR method than when using quantitative infectivity culture and that this can 198 confound antiviral efficacy determination of test compounds targeting RSV replication(29).
199
The respiratory system of human infants and young lambs have similarities, suggesting that The highest Memphis 37 titers reached in the lamb model and the WD-PBEC model in the 208 current study were 4.83 log 10 FFU/mL(31) and 7.05 log 10 TCID 50 /mL for the buffer-treated 209 cultures, respectively. As such, RSV evidently reached much higher peak viral titers in the WD-210 PBEC model compared with the lamb model under these experimental conditions. However,
211
RSV infectivity titers in nasal and/or tracheal aspirates from hospitalised infants were reported to 212 range from ~10 1 to ~10 7 pfu/mL, suggesting that virus replication in both models may reflect 213 virus growth kinetics in infants(13). In the lamb model viral titers in the lungs were markedly observed in WD-PBECs following ALX-0171 treatment might be predictive of lower clinical 220 severity scores in infants. However, this evidently remains to be confirmed. Nonetheless, our 221 data suggest that our RSV/WD-PBEC model may be of interest in helping to bridge the gap 222 between poorly-predictive pre-clinical animal models and clinical trials to further support the 223 rationale for developing promising RSV therapeutics.
224
Although palivizumab is licensed for use as a prophylactic, when tested therapeutically it 225 resulted in modest but significant reductions in viral growth kinetics from tracheal aspirates.
226
However, these viral reductions were insufficient to reduce clinical severity in patients 227 hospitalised with RSV(12, 33). Motavizumab, an affinity-matured derivative of palivizumab, 228 which was not approved for prophylactic use, was assessed as a parenterally administered 229 therapeutic following RSV infection. However, there is conflicting data on motavizumab 230 efficacy, with one study indicating a reduction in viral load(28) and another showing no effect on 231 viral load, clinical severity or length of hospitalisation(34). In pre-clinical studies motavizumab 232 and ALX-0171 was 16.8 fold (35) and 126 fold (23)more potent, respectively, than palivizumab.
233
Studies of G-specific antibodies administered post infection have shown a reduction in 234 inflammation in a mouse model of RSV infection (36, 37) . This indicates that there is potential 235 for a monoclonal antibody to be used as an effective treatment for RSV, provided the IC 50 is 236 sufficient. Route of administration is an important consideration. In a study of an adenovirus-237 based RSV vaccine, intranasal, but not intramuscular, administration elicited strong IgA 238 responses(38). Both palivizumab and motavizumab were administered intramuscularly, whereas 239 ALX-0171 is inhaled. It is likely, therefore that both the increased IC 50 values and the routes of 240 administration may explain why ALX-0171 appears to have greater therapeutic efficacy in vivo 241 than previously developed anti-RSV antibodies.
12
The determinants of RSV disease severity remain unclear and may involve multiple factors, 243 including viral load, viral strain and host susceptibility. It is also thought that the immune 244 response to RSV infection plays a major role in the severity of disease. High viral titers are 245 associated with higher levels of pro-inflammatory cytokines (13, 39) . It has been theorised that a 246 higher viral load may indirectly lead to more severe disease due to an excessive immune 247 response involving production of pro-inflammatory cytokines, leukocyte recruitment and 248 subsequent epithelial cell damage (40, 41) . This would correlate with the data from the neonatal 249 lamb model, which showed that reduced clinical severity scores were reflective of reduced viral 250 titers. However, there are other studies that show no correlation between viral load and disease 251 severity(42). It is likely that a combination of host and viral factors contribute to the overall 252 severity of disease.
253
Interestingly, the neonatal lamb model also resulted in a smaller reduction in virus copy numbers 254 in the airways compared to viral titers following ALX-0171 treatment, despite a significant 255 reduction in clinical severity scores(24). This suggests that the viable virus titer is more 256 indicative of disease severity than the viral load detected by RT-qPCR. Although viral load has 257 been correlated with disease severity in both the human challenge model and infants hospitalised 258 with RSV(43, 44), it may be more appropriate to measure replication competent virus as an 259 indicator of disease severity.
260
The development of RSV pharmaceuticals presents several challenges. These challenges relate 261 primarily to the fact that much of the pathology associated with RSV infection is thought to be 262 caused by the inflammatory immune responses to the virus infection, rather than direct viral 263 cytopathogenesis. It is imperative, therefore, that RSV antivirals result in both virus 264 neutralisation and modulation of the pro-inflammatory immune responses induced by infection. Belfast, UK. It was cultured in HEp-2 cells as previously described (25) and passaged a total of 293 three times before use. RSV Memphis 37 was originally isolated from a four-month old male in 294 Memphis, USA who presented with bronchiolitis. The virus was isolated and passaged in FDA-295 approved Vero cell cultures as previously described (26). RSV Memphis 37 was further passaged 296 seven times on HEp-2 cells. RSV titers in biological samples were determined by a tissue culture 297 infectious dose 50 (TCID 50 ) assay, as previously described (27), or by RT-qPCR (see below).
298
Infection and treatment 299 WD-PBECs were infected apically in duplicate (2 wells per condition per patient) for 2 h at 300 37 o C. Apical rinses were carried out by adding low glucose DMEM and gently pipetted up and 301 down several times. The recovered DMEM was added to cryovials and snap frozen and stored in 302 liquid nitrogen. Following the 24 hpi apical wash the cultures were treated apically with 100 µL 303 of either ALX-0171 or palivizumab at the indicated concentrations, or buffer control, for 1 h at 304 37 o C. To maintain the air-liquid interface, the treatment was removed and replaced with 10 µL of 305 the same concentration of ALX-0171 or palivizumab and incubated for 24 h, until the next apical 306 rinse. After each subsequent apical rinse 10 µL of the indicated concentration of ALX-0171 or 307 palivizumab were added to the apical surface. This was repeated every 24 h for 6 days. Table 2) . Standard curves were 317 generated using a plasmid containing the RSV-A2 genome in 10-fold dilutions. 
